4559 Zeria Pharmaceutical
- 2276
- -34-1.47%
Zeria Pharmaceutical News
Zeria Pharmaceutical: Corporate Governance Report 2024/12/27
Zeria Pharmaceutical: Notice of conclusion of a marketing and distribution agreement between Tillotts Pharma and Pioneer Pharma in the People's Republic of China
Zeria Pharmaceutical: [Delayed]Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2025[Under Japanese GAAP]
Zeria Pharmaceutical: Confirmation letter
Zeria Pharmaceutical: Half-Year Report - Term 71 (2024/04/01 - 2025/03/31)
Zeria Pharmaceutical: Summary of Financial Results for the second quarter 2025
Zeria Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
Zeria Pharmaceutical: Notice regarding revisions to earnings forecasts
Zeria Pharmaceutical: Notice regarding changes in responsibilities of executive officers
Zeria Pharmaceutical: Announcement of the new release of “Heparise W Shine”
Zeria Pharmaceutical: Notice of obtaining approval for manufacture and sale of the drug ZG-801 (Virtasa) for treating hyperkalemia
Zeria Pharmaceutical: [Delayed] Consolidated financial results for the first three months of the fiscal year ending on March 31, 2025 [based on Japanese accounting standards].
Zeria Pharmaceutical: Overview of Q1 2025 earnings report.
Zeria Pharmaceutical: 1st quarter financial results for the March 2025 period (consolidated) based on Japanese standards.
Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Zeria Pharmaceutical: Extraordinary Report
Zeria Pharmaceutical: Report on Corporate Governance June 27, 2024.
Zeria Pharmaceutical: Confirmation letter
Zeria Pharmaceutical: Internal Control Report - 70th Term (2023/04/01 - 2024/03/31)
Zeria Pharmaceutical: Securities Report - 70th period (April 1, 2023 - March 31, 2024)
No Data